Traci McCormick, MD

Friends ask me about Wegovy all the time.

“How fast will I lose weight?”

“What should I expect?”

Here is the honest answer: probably not as quickly as social media makes it seem—especially at first.

The first three months are often slow. Wegovy starts at 0.25 mg weekly and increases gradually. Many people lose somewhere in the range of 5–15 pounds during that entire stretch, although individual results vary widely.

That slow schedule is intentional. It gives your body time to adjust and helps limit side effects, which often show up after a dose increase.

Around month four, weight loss may begin to pick up as patients reach the higher doses. By six months, average weight loss in clinical trials was approximately 10–12% of starting body weight.

Then, often sometime after month nine, the pace slows again.

That does not necessarily mean the medication has stopped working. It is often a normal part of metabolic adaptation. At that point, adequate protein, strength training, sleep, and the rest of the treatment plan become increasingly important.

The trial results also deserve some context:

• In STEP 1, participants lost an average of 14.9% of their starting body weight over 68 weeks.
• In STEP 5, average weight loss was 15.2% at two years.
• Longer-term data suggest that weight tends to settle into a plateau rather than continuing to fall indefinitely.

Those are averages from clinical trials—not promises. Some people lose considerably more, some lose less, and some do not tolerate the medication well enough to continue it.

Side effects deserve honest numbers, too.

In the Wegovy trials, nausea occurred in 44% of participants, diarrhea in about 30%, vomiting in 25%, and constipation in 24%. These symptoms were usually most noticeable around dose increases and often improved with time. Approximately 4% of participants in STEP 1 stopped treatment because of gastrointestinal side effects.

Gallstones occurred in 2.6% of participants taking Wegovy compared with 1.2% taking placebo. Pancreatitis and kidney injury related to severe dehydration were uncommon—but uncommon does not mean unimportant. These are prescription medications for a reason, and patients need real medical oversight.

There is one more thing people should understand before starting: stopping the medication commonly leads to significant weight regain.

Wegovy was studied as ongoing treatment for a chronic condition—not as a quick, 12-week diet.

I am sharing this because I would rather people begin treatment with realistic expectations than feel discouraged when their experience does not match what they have seen online.

A GLP-1 can be an excellent tool. But the prescription is only one part of the plan—and anyone considering one deserves a thoughtful conversation with a qualified medical professional who knows their history.